LA 230

Drug Profile

LA 230

Latest Information Update: 01 Nov 2007

Price : $50

At a glance

  • Originator Lacer
  • Class Antihyperlipidaemics; Antihypertensives
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperlipidaemia; Hypertension

Most Recent Events

  • 01 Nov 2000 Discontinued - Preclinical for Hypertension in Spain (unspecified route)
  • 01 Nov 2000 Discontinued - Preclinical for Hyperlipidaemia in Spain (unspecified route)
  • 20 Jul 1998 No-Development-Reported for Hyperlipidaemia in Spain (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top